

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

GRANT OF WAIVER UNDER RULES 18.03, 18.48A and 18.50C OF GEM LISTING RULES

Reference is made to (i) the announcement of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 31 March 2020 (the “**2019 Unaudited Annual Results Announcement**”) in relation to the unaudited consolidated results of the Company for the year ended 31 December 2019; (ii) the announcements of the Company dated 15 May 2020 (collectively as the “**Announcements**”) in relation to the delay in publication of its audited annual results announcement (the “**2019 Audited Annual Results Announcement**”) and despatch of the annual report (the “**2019 Annual Report**”) for the year ended 31 December 2019. Unless the contexts require otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

Under the GEM Listing Rules, the Company is required (a) to send its members and other holders of its listed securities a copy of the annual report including its annual account not less than 21 days before the date of the Company’s annual general meeting and not more than three months after the date upon which the financial year ended under Rule 18.03 of the GEM Listing Rules; (b) to publish its annual report and submit a copy of its annual report to the Exchange for publication on the GEM website not later than three months after the date upon which the financial year ended under Rules 18.48A and 18.50C of the GEM Listing Rules; and (c) to lay its annual financial statements at its annual general meeting within the period of six months after the end of the financial year under Note 3 of Rule 18.03 of the GEM Listing Rules.

Under Article 53 of the Company’s articles of association (the “**Articles**”), the Company should hold its annual general meeting once each year and within six months after the prior accounting year ends.

As disclosed in the Announcements, due to the restrictions in force in parts of China to combat the outbreak of COVID-19 which resulted additional time to complete the relevant auditing process required by the auditor.

As advised by the Company's PRC legal advisors, the Company would not be in breach of any mandatory requirement(s) under the laws and regulations under the PRC as long as the Company is able to hold the AGM during the year 2020, and the Company is allowed to adjust and adopt Article 53 according to the actual circumstances and notify its Shareholders of the adjustment on the delay in holding of the AGM by way of letter(s) and/or online publication of notice(s) or announcement(s).

Applications had been made to the Stock Exchange for, and the Stock Exchange has granted the Company, the waiver to waive the requirements of (a) Rules 18.03, 18.48A and 18.50C of the GEM Listing Rules on the basis that the Company could dispatch the 2019 Annual Report on or before 30 June 2020 and (b) Note 3 of Rule 18.03 of the GEM Listing Rules subject to the Company's compliance with its Articles and the laws and regulations in the PRC under which the Company will hold the forthcoming AGM on 18 August 2020.

The Board is pleased to announce that the auditing process for the 2019 Audited Annual Results has been completed. The Company has published the 2019 Audited Annual Results Announcement and the 2019 Annual Report on 30 June 2020, and dispatched the notice of the Company dated 3 July 2020 convening the AGM to be held on 18 August 2020 to its Shareholders.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin Province, the PRC,
22 July 2020

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Yong Cai, Gao Qi Pin and Tian Jie.

This announcement, for which the directors of the Jilin Province Huinan Changlong Bio-pharmacy Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website at www.hkgem.com on the "Latest Company Announcements" page for 7 days from the day of its posting.